By Karen Roman
Ascentage Pharma Group International (Nasdaq: AAPG) said China’s National Medical Products Administration (NMPA) approved the use of lisaftoclax for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.
The authorization makes lisaftoclax the first inhibitor of its kind in receiving NMPA approval and the second approved globally, the company stated.
“As a proprietary novel drug developed through global innovation, lisaftoclax is a testament to our strength in drug development, bringing much needed change to the global landscape for Bcl-2 inhibitors,” said Dr. Dajun Yang, Ascentage Pharma Chairman and CEO.
READ MORE
Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance
Deborah Geraghty Named President & CEO of Radiant Biotherapeutics
Register for our weekly newsletter HERE
